Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Primary listing
Employees
97
Headquarters
Website
TBPH Metrics
BasicAdvanced
$698M
23.75
$0.58
0.11
-
Price and volume
Market cap
$698M
Beta
0.11
52-week high
$21.03
52-week low
$7.90
Average daily volume
759K
Financial strength
Current ratio
9.482
Quick ratio
9.302
Long term debt to equity
14.475
Total debt to equity
14.475
Interest coverage (TTM)
-13.01%
Profitability
EBITDA (TTM)
-31.164
Gross margin (TTM)
50.82%
Net profit margin (TTM)
36.53%
Operating margin (TTM)
-40.85%
Effective tax rate (TTM)
37.88%
Revenue per employee (TTM)
$830,000
Management effectiveness
Return on assets (TTM)
-5.32%
Return on equity (TTM)
14.03%
Valuation
Price to earnings (TTM)
23.747
Price to revenue (TTM)
8.566
Price to book
3
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
2.826
Free cash flow yield (TTM)
35.39%
Free cash flow per share (TTM)
4.876
Growth
Revenue change (TTM)
27.12%
Earnings per share change (TTM)
-157.38%
3-year revenue growth (CAGR)
15.86%
10-year revenue growth (CAGR)
7.31%
3-year earnings per share growth (CAGR)
-62.83%
10-year earnings per share growth (CAGR)
-20.99%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
TBPH News
AllArticlesVideos
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations
Newsfile Corp·6 days ago
Theravance Biopharma Plummets As Phase 3 Study Falls Short
Benzinga·2 weeks ago
The Excruciating Failure That Could Cause Theravance, Down 27%, To Sell Itself
Investors Business Daily·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $698M as of March 16, 2026.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 23.75 as of March 16, 2026.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.11. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.